Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ATPase copper transporting beta (ATP7B), also known as the Wilson disease protein, is a P-type ATPase primarily expressed in the liver that plays a central role in copper homeostasis [6, 11]. It functions by transporting copper from the cytosol into the trans-Golgi network for incorporation into ceruloplasmin and by facilitating the excretion of excess copper into the bile via vesicular trafficking [6, 15]. Mutations in the ATP7B gene lead to Wilson disease, a rare autosomal recessive disorder characterized by toxic copper accumulation in the liver, brain, and other tissues, resulting in hepatic cirrhosis and neuropsychiatric symptoms [5, 11]. In the context of oncology, ATP7B is a significant mediator of resistance to platinum-based chemotherapies, such as cisplatin and carboplatin, as it can sequester and efflux these agents from cancer cells [1, 3]. Current therapeutic interventions for Wilson disease include copper chelators like penicillamine and trientine, as well as zinc salts that block intestinal copper absorption [9, 10]. Emerging therapies include gene replacement strategies using adeno-associated virus (AAV) vectors to restore functional ATP7B expression in the liver [8]. Additionally, targeting ATP7B in cancer is being investigated as a strategy to overcome drug resistance and improve the efficacy of platinum-based treatments [1, 2].
In Wilson disease, therapeutic strategies focus on copper removal via chelation (e.g., penicillamine) or blocking intestinal absorption via zinc salts; gene therapies aim to restore functional ATP7B protein expression in hepatocytes [8, 10]. In oncology, ATP7B inhibition (e.g., via siRNA) is used to prevent the sequestration and efflux of platinum-based drugs, thereby increasing intracellular drug concentration and sensitizing cancer cells to chemotherapy [1, 3].
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ATPase copper transporting beta (ATP7B) (ATP7B).